FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1036-1037 October 5, 2000 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lallemant, M. PubMed Citation

The complex clinical trial described by Lallemant and colleagues in this issue of the Journal ¹ was designed to determine the optimal duration of treatment with zidovudine to prevent the transmission of human immunodeficiency virus type 1 (HIV-1) infection from mother to child in areas where the resources for health care are poor. However, the results of the study may challenge the current policy in both developed² and developing³ countries.

In this study, four regimens of zidovudine were evaluated in 1437 non–breast-feeding women in northern Thailand. The women were given either zidovudine starting at 28 weeks' gestation (the long maternal regimen) . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.